<DOC>
	<DOCNO>NCT02811263</DOCNO>
	<brief_summary>Hypoxic-ischemic encephalopathy ( HIE ) occur baby get reduce blood flow oxygen brain near time birth . This result death neurologic disability include cerebral palsy cognitive impairment half affect infant . This clinical trial determine drug erythropoietin ( Epo ) add hypothermia ( usual therapy ) improve outcome infant suffer HIE .</brief_summary>
	<brief_title>High-dose Erythropoietin Asphyxia Encephalopathy</brief_title>
	<detailed_description>Neonatal hypoxic-ischemic encephalopathy ( HIE ) refers brain injury result reduce blood oxygen flow baby 's brain near time birth . HIE affect 12,000 newborn year U.S. Half affect infant bad outcome include death , cerebral palsy cognitive impairment despite receive hypothermia , available treatment . Erythropoietin ( Epo ) cytokine remarkable neuroprotective neuroregenerative effect demonstrate animal model neonatal brain injury . In phase I trial Epo + hypothermia , investigator find Epo 1000 U/Kg/dose best reproduce pharmacokinetics neuroprotective dose animal model . Long term outcomes well expect base entry criterion MRI finding . A phase II trial compare 50 cooled infant randomize receive Epo placebo . Infants treat hypothermia + Epo less brain injury early MRI , good 12-month motor development . The investigator hypothesize Epo give cool infant moderate/severe HIE reduce combine primary outcome death neurodevelopmental impairment 49 33 % . This randomized , double-blind , placebo-controlled trial Epo therapy 500 infant HIE undergo hypothermia . Specific aim 1 ) To determine 5 dos Epo 1000 U/kg IV reduce rate death , motor cognitive deficit 2 year ; 2 ) To assess safety Epo evaluate clinical toxicity ; 3 ) To determine whether Epo decrease severity neonatal brain injury evidence early MRI circulate biomarkers brain injury . The investigator anticipate Epo confer improved 2-year neurodevelopmental outcome , safe , decrease brain injury severity determine early biomarkers .</detailed_description>
	<mesh_term>Brain Diseases</mesh_term>
	<mesh_term>Asphyxia</mesh_term>
	<mesh_term>Asphyxia Neonatorum</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>≥ 36 week gestational age Receiving active passive whole body cooling/hypothermia since &lt; 6 hour age Perinatal depression base least one following : 1 . Apgar score &lt; 5 10 minute , 2 . Need resuscitation 10 minute ( i.e. , endotracheal mask ventilation , chest compression ) , 3. pH &lt; 7.00 cord , arterial , venous blood &lt; 60 minute age 4 . Base deficit ≥ 15 mmol/L cord , arterial , venous blood &lt; 60 minute age Moderate severe encephalopathy ( base modify Sarnat exam ) present 16 hour birth Study drug unlikely administer within 26 hour birth Infant living twin ( high order multiple ) also cool Birth weight &lt; 1800 g ( e.g. , intrauterine growth restriction ) Genetic congenital condition affect neurodevelopment require multiple surgery ( e.g. , congenital viral infection , hydrops , complex congenital heart disease , severe dysmorphic feature , etc . ) Head circumference &lt; 30 cm Redirection care consider due moribund condition Patient anticipate unavailable evaluation age 2 Polycythemia ( hematocrit &gt; 65 % ) Parents diminish capacity autonomy Infant participate another interventional study ( note : include observational study )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Hours</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>